Athira Pharma Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

LONA$4.47+1.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$48,438	$90,584
Short-term investments	2,837	56,835
Prepaid expenses and other current assets	3,566	5,682
Insurance recovery receivable related to legal settlement (Note 7)	—	1,628
Total current assets	54,841	154,729
Restricted cash	631	631
Property and equipment, net	2,444	3,388
Operating lease right-of-use asset	808	1,049
Other long-term assets	55	448
Total assets	$58,779	$160,245
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$319	$129
Accrued liabilities	12,402	18,343
Accrued legal settlement (Note 7)	—	10,000
Current operating lease liability	414	368
Total current liabilities	13,135	28,840
Operating lease liability, less current portion	803	1,217
Total liabilities	13,938	30,057
Stockholders' equity:
Common stock, $0.0001 par value; 900,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; 39,040,945 and 38,172,603 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	450,982	439,739
Accumulated other comprehensive income (loss)	1	(349)
Accumulated deficit	(406,146)	(309,206)
Total stockholders' equity	44,841	130,188
Total liabilities and stockholders' equity	$58,779	$160,245

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.